

Cell Reports, Volume 32

Supplemental Information

Modulating Isoprenoid Biosynthesis Increases Lipooligosaccharides and Restores *Acinetobacter* *baumannii* Resistance to Host and Antibiotic Stress

Lauren D. Palmer, Keaton E. Minor, Joshua A. Mettlach, Emilio S. Rivera, Kelli L. Boyd, Richard M. Caprioli, Jeffrey M. Spraggins, Zachary D. Dalebroux, and Eric P. Skaar




Figure S1: *A. baumannii* AB5075 *mlaF* mutants are defective at colony formation on SDS/EDTA. Related to Figure 1. (A-B) Wild-type (WT) and *mlaF* strains were diluted and spotted to lysogeny broth (LB) plates without (A) and with (B) 0.01% SDS and 0.15% EDTA.




Figure S2: Infection at 8 h, 12 h, and histology at 36 h. Related to Figure 2. (A-B) At 8 h post infection, bacteria were enumerated from the lungs and spleens. (C-D) At 12 h post infection, bacteria were enumerated from the lungs and spleen. (E) At 8 h post infection, lungs were inflated and fixed prior to hematoxylin and eosin staining. (F) Inflammation was scored by a blinded pathologist. $n=5$; p value is by Mann-Whitney test. (G-J) At 8 h post infection, cytokines and chemokines in lung homogenates were quantified by Luminex. Medians are shown. No significance by Mann-Whitney test.




Figure S3: Constitutive expression of *pldA* and *mlaF*, and the predicted *ispB* promoter. Related to Figure 3. (A-B) Strains constitutively expressing *pldA* or *mlaF* *in trans* were grown in lysogeny broth (LB) without (A) and with (B) 0.01% SDS and 0.15 mM EDTA (n=3). Data are mean \pm SEM. (C) Predicted *ispB* promoter region containing the IS*Aba11* insertion.









Figure S4: Supplemental information for membrane fractionation and LOS quantification. Related to Figure 4. (A) Membrane separation for *A. baumannii*. (B) Total glycerophospholipids (GPL) (n=4; significance is by one-way ANOVA with Tukey's multiple comparisons). (C) NADH dehydrogenase assay for inner membrane (IM; filled symbols) and outer membrane (OM; open symbols) fractions measured decrease in NADH by absorbance at 340 nm using 50 µg total protein and normalized to time = 0 s (n=2). (D) NADH dehydrogenase activity was determined by initial rate (n=2; significance is determined by two-way ANOVA with Tukey's multiple comparisons). (E) CFU quantification of samples used for LOS analysis (n=7; no significance by one-way ANOVA). (F) Representative gel showing LOS and LPS from *A. baumannii* strains, *E. coli* DH5α, and *S. enterica* serovar Typhimurium 14028S. Data are mean ± SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.







Figure S5: Additional characterization of $\Delta mlaF$ suppressor strain phenotypes. Related to Figure 5. (A-B) Representative growth curves of the inducible *ispB* $\Delta mlaF$ strain in LB without (A) and with (B) 0.01% SDS and 0.175 mM EDTA (n=2). (C-D) Representative growth curves of strains constitutively expressing *ispB* in trans (filled symbols) in LB without (C) and with (D) 0.01% SDS and 0.1 mM EDTA (n=3). (E) Congo red exclusion to visualize capsule. Scale bar is 5 μ m. (F) Membrane potential was assessed in mid-logarithmic growth in LB (n=2-3, significance is by one-way ANOVA with Tukey's multiple comparisons). Data are mean \pm SEM. ** $p < 0.01$.

Table S1: Glycerophospholipids in the total membranes. Related to Figure 4. Data represent four biological replicates and significance was determined by 2-way ANOVA with Dunnett's multiple comparisons test. Data are mean \pm standard deviation in ng GPL/extraction (normalized to 1.5 mg protein). Significance is denoted compared to wild-type as * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; there were no statistically significant differences between $\Delta mlaF$ and $\Delta mlaF$ suppressor (supp) by 2-way ANOVA with Tukey's multiple comparisons test. GPL: glycerophospholipid; PGL: phosphatidylglycerol; aPGL: acyl-phosphatidylglycerol; PE: phosphatidylethanolamine; CL: cardiolipin.

GPL species	Total membranes		
	Wild-type	$\Delta mlaF$	$\Delta mlaF$ supp
PGL m/z 719 > 253	1317 \pm 492	5256 \pm 1642***	4276 \pm 1227**
PGL m/z 747 > 281	4861 \pm 2016	5983 \pm 1575	5668 \pm 1473
PGL m/z 773 > 281	2062 \pm 1407	2116 \pm 1286	1603 \pm 871
aPGL m/z 955 > 253	2 \pm 2	19 \pm 14	10 \pm 3
aPGL m/z 958 > 255	10 \pm 4	91 \pm 36	78 \pm 10
aPGL m/z 986 > 255	172 \pm 88	384 \pm 124	427 \pm 153
aPGL m/z 1012 > 255	36 \pm 25	82 \pm 52	55 \pm 22
PE m/z 688 > 253	88 \pm 43	486 \pm 39	324 \pm 120
PE m/z 716 > 281	10419 \pm 4055	13238 \pm 3007**	11104 \pm 2912
PE m/z 742 > 281	1760 \pm 1264	2980 \pm 2588	1568 \pm 905
CL m/z 1402 > 255	1244 \pm 881	1179 \pm 475	657 \pm 504

Table S2: Glycerophospholipids in the outer membrane fraction. Related to Figure 4. Data represent three biological replicates and significance was determined by 2-way ANOVA with Dunnett's multiple comparisons test. Data are mean \pm standard deviation in ng GPL/extraction (normalized to 0.5 mg protein). Significance is denoted compared to wild-type as * $p < 0.05$; there were no statistically significant differences between $\Delta mlaF$ and $\Delta mlaF$ suppressor (supp) by 2-way ANOVA with Tukey's multiple comparisons test. GPL: glycerophospholipid; PGL: phosphatidylglycerol; aPGL: acyl-phosphatidylglycerol; PE: phosphatidylethanolamine; CL: cardiolipin.

GPL species	Total membranes		
	Wild-type	$\Delta mlaF$	$\Delta mlaF$ supp
PGL m/z 719 > 253	82.1 \pm 35.5	295.7 \pm 61.7*	254.6 \pm 83.3*
PGL m/z 747 > 281	613.4 \pm 246.4	659.9 \pm 134.3	565.5 \pm 158.2
PGL m/z 773 > 281	139.9 \pm 10.5	130.7 \pm 86.8	63.7 \pm 34.4
aPGL m/z 955 > 253	0.2 \pm 0.1	1.2 \pm 0.5	0.7 \pm 0.1
aPGL m/z 958 > 255	1.8 \pm 0.2	10.4 \pm 3.2	8 \pm 3.8
aPGL m/z 986 > 255	15.3 \pm 3.6	30.1 \pm 5.1	29.4 \pm 6.9
aPGL m/z 1012 > 255	4.3 \pm 1.2	7.6 \pm 2.3	5.4 \pm 1.4
PE m/z 688 > 253	1.9 \pm 1.2	11.7 \pm 0.8	9.2 \pm 6
PE m/z 716 > 281	335.3 \pm 165.7	451.6 \pm 158.4	400.7 \pm 161.8
PE m/z 742 > 281	62.3 \pm 23.3	66 \pm 25	58.1 \pm 9.1
CL m/z 1402 > 255	450.8 \pm 182.1	377.1 \pm 151.1	328.5 \pm 150.2

Table S3: Oligonucleotides used in this study. Related to STAR Methods section.

Sequence	Source	Identifier
CCCGGGTCTGAAATTGAAGGC	IDT (Coralville, IA)	BM17
CCTAGTTAGTCACATATGATTATTCATAATGGCAATCA	IDT (Coralville, IA)	BM18
GAATAATGACATATGCGTCCATGAATACGATTG	IDT (Coralville, IA)	BM19
CCCGGGATCAGTTGCTGTTC	IDT (Coralville, IA)	BM20
TGATTGCCATTATGAATAATCATATGTGACTAACTAGGAG GA	IDT (Coralville, IA)	BM21
CAATCGTATTCATGGACGCATATGTCATTATTCCTCC	IDT (Coralville, IA)	BM22
CGAGGGGAACGCGTCATTT	IDT (Coralville, IA)	LP63
GCTCCACTCTGGAACAGCATTC	IDT (Coralville, IA)	LP64
GGTCGTACAGGTCGTGC	IDT (Coralville, IA)	LP69
AGACCACCACCCGGTAC	IDT (Coralville, IA)	LP70
AAAGGATCCTTTAAGAGATTTAAAAAAGGCC	IDT (Coralville, IA)	LP71
AAAGTCGACTCATGGACGAACCTCG	IDT (Coralville, IA)	LP72
CACACCCGTCCTGTGGATCCGCGTGACAAAAGAGATAT G	IDT (Coralville, IA)	LP127
TGAACGCCATCTCGAGGATATACCTGATAAAGTCAGCG	IDT (Coralville, IA)	LP143
CAGGTATATCCTCGAGATGGCGTTCAGACAATTTG	IDT (Coralville, IA)	LP144
AAGGCTCTCAAGGGCATCGGTTCGACGGTACCTTAGTAC CAGTTCATGAGTG	IDT (Coralville, IA)	LP145
GTATATCCTCGAGATATGGTACCGTCGACC	IDT (Coralville, IA)	LP148
ATACTCGAGATGAATAATAAACTCCTCTCTCG	IDT (Coralville, IA)	LP146
AAAGGTACCTCATGGACGAACCTCG	IDT (Coralville, IA)	LP147
ACCGCTGACTTTATCAGGTATATCCTCGAGATGGTCATC GATTTTAAGCAAG	IDT (Coralville, IA)	LP246
TCTCAAGGGCATCGGTTCGACGGTACCCTACTGTATTCTGA TGTAATGCAAG	IDT (Coralville, IA)	LP247
GGCGCAAGGGCTGCTAAAGGCGTCAGGCTGTCCATGCC	IDT (Coralville, IA)	LP258
TTCGAACCCAGAGTCCCCTCACAATGAAGTTGCGAAT GG	IDT (Coralville, IA)	LP259
GTTAAAAAGGATCGATCCTCTAGAGGATCCAAATTGACC TTTCACTTC	IDT (Coralville, IA)	LP270
ACTTCGAAGCAGCTCCAGCCTACACATGAAGAAAAACCC CGTATTG	IDT (Coralville, IA)	LP271
AGGAACTAAGGAGGATATTCATATGATATTATTTTGCCTA TGCATATAAATTTTTC	IDT (Coralville, IA)	LP272
ATGATTACGAATTCGAGCTCGGTACCAATAAGCTCACTG GTCGTG	IDT (Coralville, IA)	LP273
TATACATGCCCAAAGCC	IDT (Coralville, IA)	LP275
CATGCATGAGCTCACTAGTGGATCCTCACTGCCCGCTTT CCAG	IDT (Coralville, IA)	LP342

AGGTACCGGGCCCAAGCTTCTCGAGCTACTGTATTCGAT GTAATGCAAG	IDT (Coralville, IA)	LP345
GCGCTTTTGAAGCTAATTCG	IDT (Coralville, IA)	LP354
ATTTCACTTATCTGGTTGGCC	IDT (Coralville, IA)	LP355
CGATGACCATGAGCTCGAATTCTGTTTCCTG	IDT (Coralville, IA)	LP356
ATTCGAGCTCATGGTCATCGATTTTAAGC	IDT (Coralville, IA)	LP357
CAGTTTCAACTTTTACGTAGCGAC	IDT (Coralville, IA)	LP358